Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyCellularComponent	protein phosphatase 4 complex	PPP4R3A PPP4R3B PPP4R3C	5.92e-06	6	141	3	GO:0030289
GeneOntologyCellularComponent	filopodium	ADGRA2 FAT1 CYFIP1 NF2 FARP1 PALLD	1.88e-04	123	141	6	GO:0030175
Domain	SMK-1	PPP4R3A PPP4R3B	5.66e-05	2	141	2	PF04802
Domain	DUF625	PPP4R3A PPP4R3B	5.66e-05	2	141	2	IPR006887
Pathway	WP_HOMOLOGOUS_RECOMBINATION	MRE11 POLD1 BRCA2	8.18e-05	12	104	3	MM15951
Pathway	WP_DISRUPTION_OF_POSTSYNAPTIC_SIGNALING_BY_CNV	DLGAP1 GRIN2A CYFIP1 TJP1	9.70e-05	33	104	4	M39875
Pathway	KEGG_NON_HOMOLOGOUS_END_JOINING	MRE11 DCLRE1C POLL	1.06e-04	13	104	3	M7857
Pathway	WP_HOMOLOGOUS_RECOMBINATION	MRE11 POLD1 BRCA2	1.06e-04	13	104	3	M39712
Pubmed	Chr21 protein-protein interactions: enrichment in proteins involved in intellectual disability, autism, and late-onset Alzheimer's disease.	DOCK3 TET2 DLGAP1 PRSS3 MYCBP2 SYNE1 TRPS1 APBB2 GATM BTBD1 PRPF8 LRP1B PPP4R3B NF2 TJP1 DROSHA MACF1 LRBA QARS1 CNOT2 ARMC8 BRWD1	1.74e-08	1285	144	22	35914814
Pubmed	The RNA-mediated estrogen receptor α interactome of hormone-dependent human breast cancer cell nuclei.	MRE11 CASC3 USP30 POLD1 SYNE1 TRPS1 NAP1L4 ADGRG1 ZNF217 NDUFA8 CEP55 PRR12 CYFIP1 WDR11 NUP37 DROSHA CSNK1G2 SCOC FARP1 SEC24B MACF1 CNOT2 ARMC8	5.76e-08	1497	144	23	31527615
Pubmed	A Human Tyrosine Phosphatase Interactome Mapped by Proteomic Profiling.	MRE11 ACLY POLD1 NAP1L4 IDE PRPF8 PPP4R3A NDUFA11 CEP55 NUP205 CYFIP1 TJP1 TMEM131L PRMT9 PLD2 MAPK8 MAPK9 ARMC8	1.28e-07	974	144	18	28675297
Pubmed	Genome-wide CRISPR screens identify novel regulators of wild-type and mutant p53 stability.	MIS18BP1 TBKBP1 ZNF217 SOX13 PPP4R3A TBC1D8 PPP4R3B CYFIP1 SF3B3 RESF1 BRCA2 DROSHA MACF1 MAPK9	1.76e-07	588	144	14	38580884
Pubmed	The RNA binding protein MEX3A promotes tumor progression of breast cancer by post-transcriptional regulation of IGFBP4.	CASC3 TBKBP1 TRPS1 ZNF217 PRPF8 CEP55 FAT1 NF2 FARP1 MACF1	1.36e-06	332	144	10	37433992
Pubmed	A Degradation Motif in STAU1 Defines a Novel Family of Proteins Involved in Inflammation.	MRE11 MYCBP2 ACLY ICE2 ARHGAP35 PRPF8 CEP55 SF3B3 NF2 TJP1 FARP1 MACF1 QARS1 PALLD	2.07e-06	724	144	14	36232890
Pubmed	JNK-mediated phosphorylation of DLK suppresses its ubiquitination to promote neuronal apoptosis.	MYCBP2 MAPK8 MAPK9	2.40e-06	7	144	3	23979718
Pubmed	An organelle-specific protein landscape identifies novel diseases and molecular mechanisms.	EXOC6 MRE11 TBKBP1 MYCBP2 POLD1 CDH23 DPP8 PRPF8 PPP4R3A EIF3CL NUP205 CYFIP1 SF3B3 SEC24B COL14A1 POLL QARS1 CNOT2 ARMC8	2.43e-06	1321	144	19	27173435
Pubmed	SRCAP complex promotes lung cancer progression by reprograming the oncogenic transcription of Hippo-YAP/TAZ signaling pathway.	MRE11 MYCBP2 ACLY NAP1L4 ARHGAP35 CEP55 CYFIP1 NF2 TJP1 SEC24B LRBA PALLD	3.34e-06	549	144	12	38280479
Pubmed	A dual-activity topoisomerase complex regulates mRNA translation and turnover.	DOCK3 TBKBP1 MYCBP2 CFAP43 MLLT10 ARHGAP35 ADGRA2 JAK2 PRR12 FAT1 NF2 CSNK1G2 NBEAL2 JOSD1 POLL ZFYVE26 LRBA	3.55e-06	1105	144	17	35748872
Pubmed	Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing.	CASC3 TBKBP1 MYCBP2 HYKK C11orf54 TRPS1 APBB2 ADGRG1 IDE ARHGAP35 JAK2 NF2 WDR11 TJP1 FARP1 CBFA2T2 MACF1 LRBA PRKAG2 CPNE7	3.61e-06	1489	144	20	28611215
Pubmed	JNK1/2-dependent phosphorylation of angulin-1/LSR is required for the exclusive localization of angulin-1/LSR and tricellulin at tricellular contacts in EpH4 epithelial sheet.	TJP1 MAPK8 MAPK9	3.83e-06	8	144	3	24889144
Pubmed	Bmp7 functions via a polarity mechanism to promote cloacal septation.	MAPK8 MAPK9 SMAD5	3.83e-06	8	144	3	22253716
Pubmed	Effects of caloric restriction and growth hormone resistance on insulin-related intermediates in the skeletal muscle.	PRKAG2 MAPK8 MAPK9	5.73e-06	9	144	3	17301033
Pubmed	Human transcription factor protein interaction networks.	TET2 MRE11 TRPS1 NAP1L4 E2F1 ZNF217 LHX3 MLLT10 NDUFA8 SOX13 NUP205 PRR12 LHX2 FAT1 RESF1 SEC24B QARS1 CNOT2 SMAD5	7.48e-06	1429	144	19	35140242
Pubmed	BioID-based intact cell interactome of the Kv1.3 potassium channel identifies a Kv1.3-STAT3-p53 cellular signaling pathway.	MRE11 ACLY ICE2 CEP55 TBC1D8 FAM171A1 CYFIP1 SF3B3 SEC24B MACF1 LRBA QARS1 PALLD	8.47e-06	708	144	13	39231216
Pubmed	Effects of SDF-1alpha and gp120IIIB on apoptotic pathways in SK-N-SH neuroblastoma cells.	GRIN2A MAPK8 MAPK9	1.12e-05	11	144	3	16481105
Pubmed	AMPK Interactome Reveals New Function in Non-homologous End Joining DNA Repair.	MRE11 CCDC80 SOX13 PIEZO2 DCLRE1C PRKAG2	1.18e-05	121	144	6	31900314
Pubmed	α-catenin interaction with YAP/FoxM1/TEAD-induced CEP55 supports liver cancer cell migration.	NAP1L4 CEP55 CYFIP1 TJP1	1.34e-05	35	144	4	37381005
Pubmed	Impaired Annulus Fibrosus Development and Vertebral Fusion Cause Severe Scoliosis in Mice with Deficiency of c-Jun NH2-Terminal Kinases 1 and 2.	MAPK8 MAPK9 SMAD5	1.49e-05	12	144	3	30664861
Pubmed	RNF43 inhibits WNT5A-driven signaling and suppresses melanoma invasion and resistance to the targeted therapy.	MIS18BP1 NAP1L4 CEP55 TJP1 SEC24B TMEM131L MACF1 LRBA	1.49e-05	263	144	8	34702444
Pubmed	C-Jun N-terminal kinase (JNK) isoforms play differing roles in otitis media.	MAPK8 MAPK9	1.70e-05	2	144	2	25311344
Pubmed	Genetic inhibition or activation of JNK1/2 protects the myocardium from ischemia-reperfusion-induced cell death in vivo.	MAPK8 MAPK9	1.70e-05	2	144	2	16043490
Pubmed	Combined Activities of JNK1 and JNK2 in Hepatocytes Protect Against Toxic Liver Injury.	MAPK8 MAPK9	1.70e-05	2	144	2	26708719
Pubmed	Extent of hematopoietic involvement by TET2 mutations in JAK2V⁶¹⁷F polycythemia vera.	TET2 JAK2	1.70e-05	2	144	2	21273266
Pubmed	Functional in vivo interactions between JNK1 and JNK2 isoforms in obesity and insulin resistance.	MAPK8 MAPK9	1.70e-05	2	144	2	16818881
Pubmed	Loss of SMEK, a novel, conserved protein, suppresses MEK1 null cell polarity, chemotaxis, and gene expression defects.	PPP4R3A PPP4R3B	1.70e-05	2	144	2	16107728
Pubmed	Suppression of inflammatory cytokine production by carbon monoxide involves the JNK pathway and AP-1.	MAPK8 MAPK9	1.70e-05	2	144	2	12857751
Pubmed	JNK1, but not JNK2, is required in two mechanistically distinct models of inflammatory arthritis.	MAPK8 MAPK9	1.70e-05	2	144	2	21839715
Pubmed	Prevention of steatosis by hepatic JNK1.	MAPK8 MAPK9	1.70e-05	2	144	2	19945406
Pubmed	Hypothermia attenuates ischemia/reperfusion-induced endothelial cell apoptosis via alterations in apoptotic pathways and JNK signaling.	MAPK8 MAPK9	1.70e-05	2	144	2	19596001
Pubmed	Increased JNK in males compared with females in a rodent model of abdominal aortic aneurysm.	MAPK8 MAPK9	1.70e-05	2	144	2	22316675
Pubmed	c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis.	MAPK8 MAPK9	1.70e-05	2	144	2	11435459
Pubmed	The JNKs differentially regulate RNA polymerase III transcription by coordinately modulating the expression of all TFIIIB subunits.	MAPK8 MAPK9	1.70e-05	2	144	2	19620725
Pubmed	JNK inhibition reduces apoptosis and neovascularization in a murine model of age-related macular degeneration.	MAPK8 MAPK9	1.70e-05	2	144	2	23341606
Pubmed	Defective neural tube morphogenesis and altered apoptosis in the absence of both JNK1 and JNK2.	MAPK8 MAPK9	1.70e-05	2	144	2	10559486
Pubmed	JNK regulates muscle remodeling via myostatin/SMAD inhibition.	MAPK8 MAPK9	1.70e-05	2	144	2	30072727
Pubmed	Inhibition of JNK reduces G2/M transit independent of p53, leading to endoreduplication, decreased proliferation, and apoptosis in breast cancer cells.	MAPK8 MAPK9	1.70e-05	2	144	2	14724588
Pubmed	Coordination of JNK1 and JNK2 is critical for GADD45alpha induction and its mediated cell apoptosis in arsenite responses.	MAPK8 MAPK9	1.70e-05	2	144	2	16973625
Pubmed	Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms.	TET2 JAK2	1.70e-05	2	144	2	20061559
Pubmed	Single-cell approaches identify the molecular network driving malignant hematopoietic stem cell self-renewal.	TET2 JAK2	1.70e-05	2	144	2	29991556
Pubmed	c-Jun N-terminal kinase 2 suppresses pancreatic cancer growth and invasion and is opposed by c-Jun N-terminal kinase 1.	MAPK8 MAPK9	1.70e-05	2	144	2	33526844
Pubmed	Decreased expression of phosphorylated JNK in breast infiltrating ductal carcinoma is associated with a better overall survival.	MAPK8 MAPK9	1.70e-05	2	144	2	16381010
Pubmed	Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms.	TET2 JAK2	1.70e-05	2	144	2	25281607
Pubmed	Protective role of c-Jun N-terminal kinase 2 in acetaminophen-induced liver injury.	MAPK8 MAPK9	1.70e-05	2	144	2	18586006
Pubmed	JNK/SAPK Signaling Is Essential for Efficient Reprogramming of Human Fibroblasts to Induced Pluripotent Stem Cells.	MAPK8 MAPK9	1.70e-05	2	144	2	26867034
Pubmed	Does tumorigenesis select for or against mutations of the DNA repair-associated genes BRCA2 and MRE11?: considerations from somatic mutations in microsatellite unstable (MSI) gastrointestinal cancers.	MRE11 BRCA2	1.70e-05	2	144	2	16417627
Pubmed	Histone modification-mediated Lhx2 gene expression.	E2F1 LHX2	1.70e-05	2	144	2	23036195
Pubmed	Jun N-terminal kinase 1 regulates epithelial-to-mesenchymal transition induced by TGF-beta1.	MAPK8 MAPK9	1.70e-05	2	144	2	18334556
Pubmed	A pathogenic role for c-Jun amino-terminal kinase signaling in renal fibrosis and tubular cell apoptosis.	MAPK8 MAPK9	1.70e-05	2	144	2	17202416
Pubmed	The role of JNK in the development of hepatocellular carcinoma.	MAPK8 MAPK9	1.70e-05	2	144	2	21406557
Pubmed	JNK1/2 regulates ER-mitochondrial Ca2+ cross-talk during IL-1β-mediated cell death in RINm5F and human primary β-cells.	MAPK8 MAPK9	1.70e-05	2	144	2	23615449
Pubmed	Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11.	MRE11 BRCA2	1.70e-05	2	144	2	21565612
Pubmed	[Relationship between TET2 Gene SNP rs3733609 C/T and JAK2V617F Allele Burden in Patients with Myeloproliferative Neoplasms].	TET2 JAK2	1.70e-05	2	144	2	31607314
Pubmed	Signal transduction by the JNK group of MAP kinases.	MAPK8 MAPK9	1.70e-05	2	144	2	11057897
Pubmed	Silencing Jnk1 and Jnk2 accelerates basal lipolysis and promotes fatty acid re-esterification in mouse adipocytes.	MAPK8 MAPK9	1.70e-05	2	144	2	18528680
Pubmed	JNK-dependent Stat3 phosphorylation contributes to Akt activation in response to arsenic exposure.	MAPK8 MAPK9	1.70e-05	2	144	2	22696236
Pubmed	Ablation of the spindle assembly checkpoint by a compound targeting Mps1.	MAPK8 MAPK9	1.70e-05	2	144	2	16113653
Pubmed	c-Jun N-terminal kinase 1 is deleterious to the function and survival of murine pancreatic islets.	MAPK8 MAPK9	1.70e-05	2	144	2	18853132
Pubmed	Ultrafine particles from diesel engines induce vascular oxidative stress via JNK activation.	MAPK8 MAPK9	1.70e-05	2	144	2	19154785
Pubmed	Role of the MAPK/cJun NH2-terminal kinase signaling pathway in starvation-induced autophagy.	MAPK8 MAPK9	1.70e-05	2	144	2	29950132
Pubmed	Specific role of JNK in the maintenance of the tumor-initiating capacity of A549 human non-small cell lung cancer cells.	MAPK8 MAPK9	1.70e-05	2	144	2	23912840
Pubmed	JNK is required for maintaining the tumor-initiating cell-like properties of acquired chemoresistant human cancer cells.	MAPK8 MAPK9	1.70e-05	2	144	2	26235742
Pubmed	C-Jun NH(2)-terminal kinase mediates proliferation and tumor growth of human prostate carcinoma.	MAPK8 MAPK9	1.70e-05	2	144	2	12538493
Pubmed	DNA-repair genetic polymorphisms and risk of breast cancer in Cyprus.	MRE11 BRCA2	1.70e-05	2	144	2	18553220
Pubmed	Inhibition of Jun NH2-terminal kinases suppresses the growth of experimental head and neck squamous cell carcinoma.	MAPK8 MAPK9	1.70e-05	2	144	2	17908987
Pubmed	c-Jun N-terminal kinase 1/2 activation by tumor necrosis factor-alpha induces insulin resistance in human visceral but not subcutaneous adipocytes: reversal by liver X receptor agonists.	MAPK8 MAPK9	1.70e-05	2	144	2	19567513
Pubmed	Defective antiviral CD8 T-cell response and viral clearance in the absence of c-Jun N-terminal kinases.	MAPK8 MAPK9	1.70e-05	2	144	2	24673683
Pubmed	[Sodium butyrate do not induce the program of premature senescence in transformants with JNK1,2 knockout].	MAPK8 MAPK9	1.70e-05	2	144	2	19140343
Pubmed	Modulation of the response of prostate cancer cell lines to cisplatin treatment using small interfering RNA.	MAPK8 MAPK9	1.70e-05	2	144	2	23900581
Pubmed	Inhibition of c-Jun N-terminal kinase attenuates low shear stress-induced atherogenesis in apolipoprotein E-deficient mice.	MAPK8 MAPK9	1.70e-05	2	144	2	21629969
Pubmed	Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosis.	TET2 JAK2	1.70e-05	2	144	2	19903679
Pubmed	c-Jun N-terminal protein kinase 1 (JNK1), but not JNK2, is essential for tumor necrosis factor alpha-induced c-Jun kinase activation and apoptosis.	MAPK8 MAPK9	1.70e-05	2	144	2	15572687
Pubmed	Hepatotoxicity mediated by pyrazole (cytochrome P450 2E1) plus tumor necrosis factor alpha treatment occurs in c-Jun N-terminal kinase 2-/- but not in c-Jun N-terminal kinase 1-/- mice.	MAPK8 MAPK9	1.70e-05	2	144	2	21748763
Pubmed	Purinergic (ATP) signaling stimulates JNK1 but not JNK2 MAPK in osteoblast-like cells: contribution of intracellular Ca2+ release, stress activated and L-voltage-dependent calcium influx, PKC and Src kinases.	MAPK8 MAPK9	1.70e-05	2	144	2	18625195
Pubmed	Tumor necrosis factor-induced toxic liver injury results from JNK2-dependent activation of caspase-8 and the mitochondrial death pathway.	MAPK8 MAPK9	1.70e-05	2	144	2	16571730
Pubmed	c-Jun N-terminal kinase 2 promotes enterocyte survival and goblet cell differentiation in the inflamed intestine.	MAPK8 MAPK9	1.70e-05	2	144	2	28098247
Pubmed	c-Jun N-terminal kinase is upregulated in patients with hypospadias.	MAPK8 MAPK9	1.70e-05	2	144	2	23273084
Pubmed	An initial phase of JNK activation inhibits cell death early in the endoplasmic reticulum stress response.	MAPK8 MAPK9	1.70e-05	2	144	2	27122189
Pubmed	JNK2 up-regulates hypoxia-inducible factors and contributes to hypoxia-induced erythropoiesis and pulmonary hypertension.	MAPK8 MAPK9	1.70e-05	2	144	2	29118187
Pubmed	Common variants in genes of the postsynaptic FMRP signalling pathway are risk factors for autism spectrum disorders.	CAMK4 CYFIP1	1.70e-05	2	144	2	24442360
Pubmed	E2F1 mediates the downregulation of POLD1 in replicative senescence.	POLD1 E2F1	1.70e-05	2	144	2	30895337
Pubmed	c-Jun N-terminal kinase activity is required for efficient respiratory syncytial virus production.	MAPK8 MAPK9	1.70e-05	2	144	2	28062184
Pubmed	c-Jun NH(2)-terminal kinase (JNK)1 and JNK2 have distinct roles in CD8(+) T cell activation.	MAPK8 MAPK9	1.70e-05	2	144	2	11927626
Pubmed	c-Jun NH(2)-terminal kinase (JNK)1 and JNK2 signaling pathways have divergent roles in CD8(+) T cell-mediated antiviral immunity.	MAPK8 MAPK9	1.70e-05	2	144	2	11927625
Pubmed	Significance of JAK2 and TET2 mutations in myelodysplastic syndromes.	TET2 JAK2	1.70e-05	2	144	2	20171768
Pubmed	Efficient keratinocyte differentiation strictly depends on JNK-induced soluble factors in fibroblasts.	MAPK8 MAPK9	1.70e-05	2	144	2	24335928
Pubmed	Inhibition of cell proliferation and cell cycle progression by specific inhibition of basal JNK activity: evidence that mitotic Bcl-2 phosphorylation is JNK-independent.	MAPK8 MAPK9	1.70e-05	2	144	2	14704147
Pubmed	Comparison of clinicopathologic findings according to JAK2 V617F mutation in patients with essential thrombocythemia.	JAK2 MAPK9	1.70e-05	2	144	2	19093167
Pubmed	Differential roles of JNK in ConA/GalN and ConA-induced liver injury in mice.	MAPK8 MAPK9	1.70e-05	2	144	2	18772342
Pubmed	c-Jun NH2-terminal kinase-2 mediates osmotic stress-induced tight junction disruption in the intestinal epithelium.	MAPK8 MAPK9	1.70e-05	2	144	2	20595622
Pubmed	c-Jun NH2-terminal kinase is required for lineage-specific differentiation but not stem cell self-renewal.	MAPK8 MAPK9	1.70e-05	2	144	2	20065035
Pubmed	Inhibited neurogenesis in JNK1-deficient embryonic stem cells.	MAPK8 MAPK9	1.70e-05	2	144	2	16314504
Pubmed	The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms.	TET2 JAK2	1.70e-05	2	144	2	21173100
Pubmed	JNK1 and 2 play a negative role in reprogramming to pluripotent stem cells by suppressing Klf4 activity.	MAPK8 MAPK9	1.70e-05	2	144	2	24211391
Pubmed	Protective role of c-Jun N-terminal kinase-2 (JNK2) in ibuprofen-induced acute liver injury.	MAPK8 MAPK9	1.70e-05	2	144	2	30264435
Pubmed	Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2.	JAK2 JOSD1	1.70e-05	2	144	2	34326465
Pubmed	Mutation in TET2 in myeloid cancers.	TET2 JAK2	1.70e-05	2	144	2	19474426
Pubmed	c-Jun N-terminal kinase 2 (JNK2) antagonizes the signaling of differentiation by JNK1 in human myeloid leukemia cells resistant to vitamin D.	MAPK8 MAPK9	1.70e-05	2	144	2	19339050
Pubmed	Chromosomal abnormalities in transformed Ph-negative myeloproliferative neoplasms are associated to the transformation subtype and independent of JAK2 and the TET2 mutations.	TET2 JAK2	1.70e-05	2	144	2	20629097
Cytoband	Xp22.12	BCLAF3 MAP3K15	2.70e-04	8	144	2	Xp22.12
Cytoband	11q21	MRE11 C11orf54 MAML2	3.64e-04	44	144	3	11q21
GeneFamily	Cadherin related	CDHR2 CDH23 FAT1	6.28e-05	17	84	3	24
GeneFamily	WD repeat domain containing\|BEACH domain containing	NBEAL2 LRBA	7.52e-04	9	84	2	1230
GeneFamily	LIM class homeoboxes	LHX3 LHX2	1.37e-03	12	84	2	522
GeneFamily	WD repeat domain containing	CFAP43 WDR11 NUP37 NBEAL2 LRBA BRWD1	1.38e-03	262	84	6	362
GeneFamily	Mitogen-activated protein kinases	MAPK8 MAPK9	1.61e-03	13	84	2	651
GeneFamily	Ankyrin repeat domain containing\|FERM domain containing	JAK2 NF2 FARP1	1.62e-03	50	84	3	1293
Coexpression	GSE11961_GERMINAL_CENTER_BCELL_DAY7_VS_PLASMA_CELL_DAY7_DN	EXOC6 C11orf54 POLD1 KBTBD7 CYFIP1 WDR11 TMEM131L CCDC9 BRWD1	1.62e-06	200	143	9	M9361
Coexpression	GSE3982_EOSINOPHIL_VS_DC_UP	CASC3 DLGAP1 SYNE1 MLLT10 PPP4R3B DCLRE1C TMEM131L COL14A1	1.42e-05	199	143	8	M5399
Coexpression	GOBERT_OLIGODENDROCYTE_DIFFERENTIATION_UP	MRE11 DLGAP1 MIS18BP1 POLD1 TRPS1 E2F1 CENPK CEP55 DDIAS BRCA2 NUP37 PALLD ZNF367	1.79e-05	578	143	13	M2368
Coexpression	BUSSLINGER_GASTRIC_IMMUNE_CELLS	GPR155 MIS18BP1 MYCBP2 SYNE1 TRPS1 NAP1L4 ZNF217 BTBD1 ARHGAP35 DPP8 PRPF8 PPP4R3A PPP4R3B SF3B3 RESF1 CSNK1G2 NBEAL2 TMEM131L MACF1 LRBA CNOT2 BRWD1	1.98e-05	1492	143	22	M40023
Coexpression	GOBERT_OLIGODENDROCYTE_DIFFERENTIATION_UP	MRE11 DLGAP1 MIS18BP1 POLD1 TRPS1 E2F1 CENPK CEP55 DDIAS BRCA2 NUP37 PALLD ZNF367	2.50e-05	597	143	13	MM1309
Coexpression	DESCARTES_FETAL_LIVER_STELLATE_CELLS	ADAMTSL1 MXRA8 MDGA2 ADGRA2 LHX2 GPR153 DIO3	2.89e-05	160	143	7	M40233
Coexpression	MARSON_BOUND_BY_E2F4_UNSTIMULATED	MRE11 ICE2 MDM1 E2F1 CFAP43 CENPK ZFPL1 CEP55 BRCA2 NUP37 DROSHA JOSD1 ZNF367 ARMC8	3.81e-05	714	143	14	M1744
Coexpression	HAMAI_APOPTOSIS_VIA_TRAIL_UP	MIS18BP1 MYCBP2 ICE2 ADGRG1 DPP8 CENPK CEP55 PIEZO2 RESF1 DCLRE1C WDR11 SCOC PALLD	6.56e-05	656	143	13	M18979
Coexpression	DUTERTRE_ESTRADIOL_RESPONSE_24HR_UP	TET2 MRE11 POLD1 E2F1 CEP55 JAK2 DDIAS BRCA2 ZNF367	7.37e-05	323	143	9	M2156
Coexpression	GSE3982_BCELL_VS_NKCELL_DN	SYNE1 ARHGAP35 LRP1B SOX13 TBC1D8 NHLH2 PALLD	1.08e-04	197	143	7	M5548
Coexpression	GSE3982_MAST_CELL_VS_TH1_UP	PILRA BTBD1 SOX13 FAM171A1 PPP4R3B FAT1 DROSHA	1.14e-04	199	143	7	M5453
Coexpression	GSE10239_KLRG1INT_VS_KLRG1HIGH_EFF_CD8_TCELL_DN	MDGA2 CAMK1G GRIN2A IDE MLLT10 KBTBD7 MAPK9	1.14e-04	199	143	7	M3070
Coexpression	GSE24574_NAIVE_VS_TCONV_CD4_TCELL_UP	DLGAP1 SYNE1 MXRA8 ADA SUOX JOSD1 COL14A1	1.18e-04	200	143	7	M8328
Coexpression	GSE27786_LSK_VS_ERYTHROBLAST_UP	MYCBP2 MTF2 POLD1 GATM BTBD1 PHKA2 CNOT2	1.18e-04	200	143	7	M4757
Coexpression	GSE3039_ALPHABETA_CD8_TCELL_VS_B1_BCELL_UP	TBPL1 MDM1 MLLT10 PPP4R3B RESF1 TMEM131L SMAD5	1.18e-04	200	143	7	M6447
Coexpression	GSE3982_DC_VS_MAC_UP	TBKBP1 TBC1D8 RESF1 SUOX DCLRE1C FARP1 DDX43	1.18e-04	200	143	7	M5458
Coexpression	PUJANA_BRCA2_PCC_NETWORK	MRE11 MTF2 POLD1 E2F1 LCT ADA NUP205 FAT1 BRCA2 TMEM131L	1.21e-04	426	143	10	M9516
Coexpression	ZHANG_BREAST_CANCER_PROGENITORS_UP	MIS18BP1 C11orf54 TRPS1 CEP55 BCLAF3 PPP4R3B WDR11 LRBA FAM199X ZNF367	1.41e-04	434	143	10	M15150
CoexpressionAtlas	FacebaseRNAseq_e10.5_Maxillary Arch_top-relative-expression-ranked_2500_k-means-cluster#5	CASC3 TBPL1 ICE2 NAP1L4 MDGA2 BTBD1 ARHGAP35 ADA CENPK BCLAF3 BRCA2 DCLRE1C SEC24B NHLH2 MACF1 PRKAG2 CNOT2	8.88e-07	629	140	17	Facebase_RNAseq_e10.5_Maxillary Arch_2500_K5
CoexpressionAtlas	facebase_RNAseq_e10.5_MandArch_2500_K1	MIS18BP1 MYH7B TBPL1 ACLY ICE2 MDM1 TRPS1 E2F1 BTBD1 ADA CENPK PPP4R3B DDIAS RESF1 BRCA2 NUP37 SCOC TMEM131L MACF1 CLMP LRBA MAPK8 SMAD5 BRWD1	1.87e-06	1241	140	24	facebase_RNAseq_e10.5_MandArch_2500_K1
CoexpressionAtlas	facebase_RNAseq_e10.5_MaxArch_2500_K3	GPR155 TET2 MIS18BP1 CAMK4 ACLY ICE2 MDM1 TRPS1 ADGRG1 E2F1 ADA CENPK PPP4R3A BCLAF3 PPP4R3B DDIAS RESF1 BRCA2 SCOC TMEM131L CLMP LRBA MAPK8 SMAD5	2.19e-06	1252	140	24	facebase_RNAseq_e10.5_MaxArch_2500_K3
CoexpressionAtlas	facebase_RNAseq_e10.5_MandArch_2500	DOCK3 MIS18BP1 MYH7B TBPL1 ACLY ICE2 MDM1 TRPS1 E2F1 BTBD1 ADA CENPK PPP4R3B DDIAS RESF1 BRCA2 NUP37 SCOC NBEAL2 TMEM131L MACF1 CLMP LRBA MAPK8 SMAD5 BRWD1	3.32e-06	1468	140	26	facebase_RNAseq_e10.5_MandArch_2500
CoexpressionAtlas	alpha beta T cells, T.ISP.Th, 4- 8+ TCR-/lo 24hi, Thymus, avg-3	MIS18BP1 MTF2 CAMK4 POLD1 MDM1 ADGRG1 E2F1 ADA CENPK CEP55 NUP205 DDIAS BRCA2	4.03e-06	417	140	13	GSM399403_500
CoexpressionAtlas	FacebaseRNAseq_e10.5_Maxillary Arch_top-relative-expression-ranked_1000_k-means-cluster#3	MIS18BP1 ICE2 SYNE1 MDM1 TRPS1 ADA CENPK BCLAF3 BRCA2 MACF1 LRBA SMAD5 BRWD1	5.91e-06	432	140	13	Facebase_RNAseq_e10.5_Maxillary Arch_1000_K3
CoexpressionAtlas	dev gonad_e13.5_F_MeioticGermCell_Oct_top-relative-expression-ranked_1000	DOCK3 MRE11 MIS18BP1 ICE2 ZNF217 IDE CENPK BCLAF3 PHKA2 DDIAS SF3B3 BRCA2 PRMT9 MAP3K15 DDX43 LRBA PRKAG2 BRWD1	7.74e-06	820	140	18	gudmap_dev gonad_e13.5_F_MeioticGermCell_Oct_1000
CoexpressionAtlas	FacebaseRNAseq_e10.5_Maxillary Arch_top-relative-expression-ranked_1000	GPR155 CASC3 MIS18BP1 CAMK4 ICE2 SYNE1 MDM1 TRPS1 NAP1L4 ADGRG1 ADA CENPK BCLAF3 LHX2 BRCA2 NHLH2 MACF1 LRBA SMAD5 BRWD1	7.83e-06	989	140	20	Facebase_RNAseq_e10.5_Maxillary Arch_1000
CoexpressionAtlas	dev gonad_e12.5_F_GermCellOvary_Oct_top-relative-expression-ranked_1000	DOCK3 MRE11 MIS18BP1 MDM1 ZNF217 IDE NUP205 BCLAF3 PHKA2 DDIAS SF3B3 BRCA2 DROSHA CBFA2T2 PRMT9 MAP3K15 DDX43 BRWD1	8.00e-06	822	140	18	gudmap_dev gonad_e12.5_F_GermCellOvary_Oct_1000
CoexpressionAtlas	FacebaseRNAseq_e9.5_Mandibular Arch_top-relative-expression-ranked_2500_k-means-cluster#2	MYCBP2 HYKK TBPL1 ICE2 MDM1 NAP1L4 BTBD1 CENPK DDIAS DCLRE1C SEC24B MACF1 CNOT2 BRWD1	2.24e-05	564	140	14	Facebase_RNAseq_e9.5_Mandibular Arch_2500_K2
CoexpressionAtlas	dev gonad_e13.5_M_GermCell_Oct_top-relative-expression-ranked_1000	DOCK3 MIS18BP1 MTF2 ICE2 ZNF217 IDE NUP205 BCLAF3 DDIAS SF3B3 BRCA2 NUP37 DROSHA JOSD1 PRMT9 MAP3K15 DDX43	2.50e-05	810	140	17	gudmap_dev gonad_e13.5_M_GermCell_Oct_1000
CoexpressionAtlas	facebase_RNAseq_e10.5_Emin_MedNas_2500_K1	MIS18BP1 ICE2 MDM1 TRPS1 ADGRG1 E2F1 MDGA2 ADA CENPK BCLAF3 BRCA2 SCOC SPON1 CBFA2T2 TMEM131L MACF1 MAPK8 SMAD5 BRWD1	6.97e-05	1060	140	19	facebase_RNAseq_e10.5_Emin_MedNas_2500_K1
CoexpressionAtlas	FacebaseRNAseq_e10.5_Maxillary Arch_top-relative-expression-ranked_500	GPR155 MIS18BP1 CAMK4 SYNE1 MDM1 TRPS1 ADGRG1 ADA BRCA2 NHLH2 LRBA SMAD5	1.04e-04	492	140	12	Facebase_RNAseq_e10.5_Maxillary Arch_500
CoexpressionAtlas	DevelopingLowerUrinaryTract_e14.5_ urogenital sinus_emap-5517_k-means-cluster#4_top-relative-expression-ranked_1000	MYCBP2 TRPS1 IDE NF2 SCOC SEC24B COL14A1 SERAC1 MAPK8 SMAD5	2.43e-04	385	140	10	gudmap_developingLowerUrinaryTract_e14.5_ urogenital sinus_1000_k4
CoexpressionAtlas	FacebaseRNAseq_e10.5_Maxillary Arch_top-relative-expression-ranked_500_k-means-cluster#3	MIS18BP1 SYNE1 MDM1 TRPS1 ADA BRCA2 LRBA SMAD5	2.96e-04	255	140	8	Facebase_RNAseq_e10.5_Maxillary Arch_500_K3
ToppCell	renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Fibroblast-high_collagen-matrisome_fibroblast-\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	DLGAP1 ADAMTSL1 CAMK4 ANO1 CAMK1G SOX13 PIEZO2 SPON1 COL14A1 CLMP PALLD	4.57e-11	196	144	11	a12dd986df65c36f248cf10815c3b8b6238613b0
ToppCell	renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Fibroblast-high_collagen-matrisome_fibroblast\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	DLGAP1 ADAMTSL1 CAMK4 ANO1 CAMK1G SOX13 PIEZO2 SPON1 COL14A1 CLMP PALLD	4.57e-11	196	144	11	3e6803587d8566fd08cb8b290be3b6461743d79c
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Mesenchymal-Fibroblast-high_collagen-matrisome_fibroblast-\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	DLGAP1 ADAMTSL1 CAMK4 CAMK1G PIEZO2 SPON1 COL14A1 CLMP PALLD	1.47e-08	194	144	9	240d122dcb9dd1ab2867503ad85869853adcacae
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Mesenchymal-Fibroblast-high_collagen-matrisome_fibroblast\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	DLGAP1 ADAMTSL1 CAMK4 CAMK1G PIEZO2 SPON1 COL14A1 CLMP PALLD	1.47e-08	194	144	9	ae7df037592f1c20c9d32be15fe6fc3c562ebeb1
ToppCell	renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	ADAMTSL1 CAMK4 ANO1 ADGRA2 PIEZO2 SPON1 COL14A1 CLMP PALLD	1.54e-08	195	144	9	d9a5c75d31c6e8bb1e1ab7fd115ac5deb5fb1c8d
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Mesenchymal-Fibroblast\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	DLGAP1 ADAMTSL1 CAMK4 CAMK1G PIEZO2 SPON1 COL14A1 CLMP PALLD	1.54e-08	195	144	9	44d7bef5f59c2c2bad1392ee6aabdaa5d7f531d9
ToppCell	LPS_IL1RA-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	MYCBP2 SYNE1 MXRA8 CCDC80 SPON1 MACF1 COL14A1 CLMP PALLD	1.84e-08	199	144	9	a7dd94b172c973a131a6792f8ccd9bfe44d984ac
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell_cycling-Cycling_Proximal_Tubule_Epithelial_Cell_S-high\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	POLD1 E2F1 CENPK NDUFA11 CEP55 DDIAS BRCA2 ZNF367	8.18e-08	169	144	8	121768fc51fc3441ec725346a1bbe29e21d05971
ToppCell	COVID-19_Mild-NK_activated\|COVID-19_Mild / Disease condition and Cell class	SYNE1 ADGRG1 PPP4R3A EIF3CL PPP4R3B NBPF10 TMEM131L MACF1	1.51e-07	183	144	8	22bd05135906d0ecc4ba8c2e0a666093d1bf3b8f
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	ANO1 APBB2 MDGA2 GRIN2A ADGRA2 SOX13 PIEZO2 TMEM131L	1.64e-07	185	144	8	51dfe6ac7df8b330343b37e3bee71e5c65267189
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte-\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	ANO1 APBB2 MDGA2 GRIN2A ADGRA2 SOX13 PIEZO2 TMEM131L	1.64e-07	185	144	8	a8c02cec3c414f3a0da9f2d6d28ce563b0030705
ToppCell	LPS-IL1RA-Stromal_mesenchymal-Matrix_Fibroblast-Diff_MatrixFB\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	DLGAP1 MXRA8 CCDC80 PIEZO2 SPON1 COL14A1 CLMP PALLD	1.93e-07	189	144	8	e9d5e858e320c6e9913c1ea6a54967d21eda605f
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Fibroblast-Collagen-low_Matrisome-low_fibroblast\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	DLGAP1 ADAMTSL1 CAMK4 CAMK1G PIEZO2 COL14A1 CLMP PALLD	2.01e-07	190	144	8	2306aa9dbeaef3be8484a5b236605de23cd75d4c
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Fibroblast-Collagen-low_Matrisome-low_fibroblast-\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	DLGAP1 ADAMTSL1 CAMK4 CAMK1G PIEZO2 COL14A1 CLMP PALLD	2.01e-07	190	144	8	1f83f7f24288a3b9ab33c2e113e845dba96adc8a
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Fibroblast\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	DLGAP1 ADAMTSL1 CAMK4 GRIN2A PIEZO2 COL14A1 CLMP PALLD	2.09e-07	191	144	8	a58c75e9580139fb370b498d95660f10f3a2a27b
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Fibroblast-high_collagen-matrisome_fibroblast\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	DLGAP1 ADAMTSL1 CAMK4 PIEZO2 SPON1 COL14A1 CLMP PALLD	2.18e-07	192	144	8	9093a9e94a25682d109a7f6edc256a25a61103a0
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	ANO1 CCDC80 GRIN2A ADGRA2 PIEZO2 SPON1 CLMP PALLD	2.18e-07	192	144	8	d3c1ad4667a1e223a83ca0fcd5991a0b96f1199a
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Fibroblast-high_collagen-matrisome_fibroblast-\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	DLGAP1 ADAMTSL1 CAMK4 PIEZO2 SPON1 COL14A1 CLMP PALLD	2.18e-07	192	144	8	9ed5d49621ec1aa01716dc369bba1450b5f015f5
ToppCell	LPS-IL1RA-Stromal_mesenchymal-Matrix_Fibroblast\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	DLGAP1 MXRA8 CCDC80 PIEZO2 SPON1 COL14A1 CLMP PALLD	2.18e-07	192	144	8	f4fc2b0121f879bab2bee99dfb5ff2c3ca1c0e1b
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Mesenchymal\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	ADAMTSL1 CAMK4 ANO1 GRIN2A ADGRA2 COL14A1 CLMP PALLD	2.27e-07	193	144	8	f1199518c3626fd29bfce65070dd21a660671213
ToppCell	Children_(3_yrs)-Mesenchymal-matrix_fibroblast_1_cell-D032\|Children_(3_yrs) / Lineage, Cell type, age group and donor	DLGAP1 ANO1 CDH23 PIEZO2 SPON1 MACF1 CLMP PALLD	2.27e-07	193	144	8	b3ad5ff480d99217f36cc7471e5a96a519ddb409
ToppCell	LPS-antiTNF-Stromal_mesenchymal\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	DLGAP1 SYNE1 MXRA8 CCDC80 PIEZO2 SPON1 COL14A1 PALLD	2.36e-07	194	144	8	6e13549f697f7478b34fe71f7dd9d63c5d3db22e
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Mesenchymal\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	DLGAP1 ADAMTSL1 CAMK4 ADGRA2 SPON1 COL14A1 CLMP PALLD	2.45e-07	195	144	8	d8ebb94f30d4a655d6b29dd6a3076be2403d2356
ToppCell	PCW_13-14-Mesenchymal-Mesenchymal_cycling-mes_proliferating1_(3)\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	MRE11 MIS18BP1 POLD1 E2F1 CENPK DDIAS BRCA2 ZNF367	2.55e-07	196	144	8	df366d76ea55f49e349d622effa57c1535df8400
ToppCell	renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Fibroblast\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	ADAMTSL1 CAMK4 ANO1 PIEZO2 SPON1 COL14A1 CLMP PALLD	2.65e-07	197	144	8	6d027119a5f7ca2aac1b10837e43f9a2bb54db85
ToppCell	renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Fibroblast-Collagen-low_Matrisome-low_fibroblast\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	DLGAP1 ADAMTSL1 CAMK4 PIEZO2 SPON1 COL14A1 CLMP PALLD	2.65e-07	197	144	8	b349f8e96d61a4c296af64711e11fc44459a9413
ToppCell	renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Fibroblast-Collagen-low_Matrisome-low_fibroblast-\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	DLGAP1 ADAMTSL1 CAMK4 PIEZO2 SPON1 COL14A1 CLMP PALLD	2.65e-07	197	144	8	c2e390653d5dee7e731c1840cfdab41987dede9b
ToppCell	LPS_IL1RA_TNF-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB\|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type	SYNE1 MXRA8 CCDC80 SPON1 MACF1 COL14A1 CLMP PALLD	2.86e-07	199	144	8	30d3e8c0681ec11f86dd38c5f48d21187a1b4f90
ToppCell	LPS_IL1RA_TNF-Mesenchymal_fibroblastic-Fibroblasts-Activated_MatrixFB\|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type	POLD1 SYNE1 MXRA8 CCDC80 MACF1 COL14A1 CLMP PALLD	2.86e-07	199	144	8	e1849505b92820a219c5a2c35492bdd55579fb48
ToppCell	cellseq-Mesenchymal-Fibroblastic\|cellseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	MXRA8 CCDC80 PIEZO2 SPON1 MACF1 COL14A1 CLMP PALLD	2.97e-07	200	144	8	8978867bf69c830b1e48cac2ad6b512dbe60f149
ToppCell	LPS_IL1RA_TNF-Mesenchymal_fibroblastic-Fibroblasts\|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type	SYNE1 MXRA8 CCDC80 SPON1 MACF1 COL14A1 CLMP PALLD	2.97e-07	200	144	8	44a68bacdb3d5bf563bd35952176995850933a81
ToppCell	LPS_IL1RA_TNF-Mesenchymal_fibroblastic\|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type	SYNE1 MXRA8 CCDC80 SPON1 MACF1 COL14A1 CLMP PALLD	2.97e-07	200	144	8	dc61016c61729f69649cfb21f6264e685ce83dea
ToppCell	Mild/Remission-B_naive-1\|Mild/Remission / disease group and sub_cluster of B and Plasma cells(res = 0.5)	ICE2 PPP4R3A EIF3CL BCLAF3 PPP4R3B NBPF10 TMEM131L	4.32e-07	143	144	7	bd3f5fbd4e9e4dc414682db5607494f3ce988deb
ToppCell	facs-Lung-24m-Endothelial-capillary_endothelial-capillary_endothelial_cell-capillary_type_1_endothelial_cell\|24m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	DOCK3 CDHR2 MDGA2 NEB LRP1B ABCB11 OPN5	1.00e-06	162	144	7	bf886e22ff2a20353499004b53f25fb9e6574896
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell_cycling\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	E2F1 CENPK CEP55 DDIAS BRCA2 OPN5 ZNF367	1.04e-06	163	144	7	3f434015c0cbefb31eeda133c34f75384c5f7e22
ToppCell	E17.5-Mesenchymal-developing_mesenchymal_cell-mesenchymal_immature_unknown_1\|E17.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	GRIN2A GDF9 FAM171A1 SPON1 MACF1 COL14A1 PALLD	1.38e-06	170	144	7	7fa022471e14ac8a3bc147c793368a4d56a8e591
ToppCell	PND03-Mesenchymal-Mesenchymal_structural-Fibroblastic-AF1-AF1_prolif\|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	MXRA8 CAMK1G CENPK SPON1 MACF1 PALLD ZNF367	1.38e-06	170	144	7	e20568c8f3f17d94de78229617eb2f7e4c5af2bc
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Cycling_Myofibroblast-\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	TOGARAM2 ANO1 E2F1 CENPK CEP55 BRCA2 MINAR1	1.44e-06	171	144	7	b0373ed8283ee1792b6a490bff93906546978593
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Cycling_Myofibroblast\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	TOGARAM2 ANO1 E2F1 CENPK CEP55 BRCA2 MINAR1	1.44e-06	171	144	7	b92963f9f247d2e5e2e6c51c6dbf70e527cd2f55
ToppCell	3'-Parenchyma_lung-Mesenchymal-Mesenchymal_Myocytic-myocytic_fibroblast-Myofibroblasts-Myofibroblasts_L.2.3.2.2\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	MXRA8 ANO1 SPON1 DIO3 MACF1 MAML2 PALLD	1.68e-06	175	144	7	1799a7be623dc3bf53ba580a7c47d2619969d708
ToppCell	kidney_cells-Hypertensive_with+without-CKD-Mesenchymal-glomerular_mesenchymal_cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	SYNE1 MXRA8 ANO1 CCDC80 CAMK1G ADGRA2 PIEZO2	2.10e-06	181	144	7	a2058d658f07ab6f0a28d2622f3090b4cde6f763
ToppCell	renal_papilla_nuclei-Adult_normal_reference-Mesenchymal-Fibroblast-Degenerative_Fibroblast\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	ADAMTSL1 MXRA8 CAMK1G ADGRA2 COL14A1 CLMP PALLD	2.10e-06	181	144	7	6d1f1ad35778a2a227f966f11f6edd8e89452576
ToppCell	kidney_cells-Hypertensive_with+without-CKD-Mesenchymal-glomerular_mesenchymal_cell-Mesangial_Cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	SYNE1 MXRA8 ANO1 CCDC80 CAMK1G ADGRA2 PIEZO2	2.10e-06	181	144	7	526e858a848470b6d2d5248788004d9735ed3add
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Fibroblast-kidney_interstitial_fibroblast\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	ADAMTSL1 CCDC80 GRIN2A DIO3 COL14A1 CLMP PALLD	2.34e-06	184	144	7	e061e85c4bb19f49f6451ddd7a9077d7378ee365
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Myocytic_interstitial_cell-Cycling_Myofibroblast-\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	ADGRA2 CENPK CEP55 PIEZO2 BRCA2 CLMP ZNF367	2.60e-06	187	144	7	e41e39fd3791acf8ae5376cc5061e196d96868ae
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Myocytic_interstitial_cell-Cycling_Myofibroblast\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	ADGRA2 CENPK CEP55 PIEZO2 BRCA2 CLMP ZNF367	2.60e-06	187	144	7	cefa211ef224e803ea9467882e2ca74d0b1492f1
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Mesenchymal-glomerular_mesenchymal_cell-Mesangial_Cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	SYNE1 ANO1 APBB2 MDGA2 CAMK1G ADGRA2 PIEZO2	2.60e-06	187	144	7	15d6e158562d7d85af3ceaf955439b379c8fce81
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Mesenchymal-glomerular_mesenchymal_cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	SYNE1 ANO1 APBB2 MDGA2 CAMK1G ADGRA2 PIEZO2	2.60e-06	187	144	7	f62074b631fd45ad299c69d71b09267b04d656ee
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Mesenchymal-glomerular_mesenchymal_cell-Mesangial_Cell-mesangial_typical-aged\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	SYNE1 ANO1 APBB2 MDGA2 CAMK1G ADGRA2 PIEZO2	2.70e-06	188	144	7	32f22a4d8cb98fd8b8fa0fbf28ef9266d711d081
ToppCell	RA-11._Adipocyte\|World / Chamber and Cluster_Paper	MYCBP2 ACLY TRPS1 CDH23 LRP1B SPON1 CLMP	2.70e-06	188	144	7	4dac9d636e5cad4cda540b93d4bfed6b5732c880
ToppCell	LPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Diff_MatrixFB\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	DLGAP1 MXRA8 CCDC80 PIEZO2 SPON1 COL14A1 CLMP	2.79e-06	189	144	7	a153b83314cf52808f685296cff8c95af3f4983d
ToppCell	PND07-28-samps-Mesenchymal-Matrix_fibroblast\|PND07-28-samps / Age Group, Lineage, Cell class and subclass	MXRA8 CCDC80 CAMK1G FAM171A1 SPON1 MACF1 PALLD	2.79e-06	189	144	7	dc5164591dea45b420798b94dda211be03daa70c
ToppCell	Adult-Mesenchymal-matrix_fibroblast_2_cell-D175\|Adult / Lineage, Cell type, age group and donor	ADAMTSL1 MXRA8 CCDC80 PIEZO2 SPON1 COL14A1 CLMP	2.89e-06	190	144	7	7dcca3469f3a3b70db0420cb94f7765f39492f06
ToppCell	PND07-28-samps-Mesenchymal-Matrix_fibroblast-FB-3\|PND07-28-samps / Age Group, Lineage, Cell class and subclass	MXRA8 CCDC80 CAMK1G FAM171A1 SPON1 MACF1 PALLD	2.89e-06	190	144	7	1196b8ea2c44c7c80f5ee589dd517e6a413f2077
ToppCell	PBMC-Severe-cDC_12\|Severe / Compartment, Disease Groups and Clusters	POLD1 E2F1 CENPK CEP55 NUP205 BRCA2 ZNF367	2.89e-06	190	144	7	84ee185939bdefb10705b621a70da27701eadcee
ToppCell	LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Diff_MatrixFB\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	DLGAP1 MXRA8 CCDC80 PIEZO2 SPON1 COL14A1 CLMP	2.89e-06	190	144	7	841cd55861b43578d704418b9bc0af2e8b88323a
ToppCell	LPS_only-Stromal_mesenchymal-Matrix_Fibroblast-Diff_MatrixFB\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	DLGAP1 MXRA8 CCDC80 PIEZO2 SPON1 COL14A1 CLMP	2.89e-06	190	144	7	d60395739458d7f47a3350ade751fe3819500320
ToppCell	Control-Stromal_mesenchymal\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	DOCK3 DLGAP1 ANO1 CCDC80 SPON1 COL14A1 PALLD	2.99e-06	191	144	7	14057205ddb9b4bbc582d1358d13cf36d979a61b
ToppCell	renal_papilla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Fibroblast-Collagen-low_Matrisome-low_fibroblast\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	TRPS1 ANO1 CAMK1G PIEZO2 SPON1 CLMP PALLD	2.99e-06	191	144	7	1caf726bd07fdca389e678fc16304a6ef1790423
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	ANO1 APBB2 MDGA2 ADGRA2 SOX13 PIEZO2 TMEM131L	2.99e-06	191	144	7	7b0d42a877540dbb346a76a62403e0d5d3e07fa6
ToppCell	renal_papilla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Fibroblast-Collagen-low_Matrisome-low_fibroblast-\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	TRPS1 ANO1 CAMK1G PIEZO2 SPON1 CLMP PALLD	2.99e-06	191	144	7	3d60c46bced2984c27a1fcf2910bc38b31fb0148
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte-\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	ANO1 APBB2 MDGA2 ADGRA2 SOX13 PIEZO2 TMEM131L	2.99e-06	191	144	7	cd854b9c426924fdc84bf7f411f6dea447143e79
ToppCell	LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	DLGAP1 MXRA8 CCDC80 PIEZO2 SPON1 COL14A1 CLMP	3.10e-06	192	144	7	6f4ef24dab544681304b7f8a9dc073e7edaa4cf5
ToppCell	LPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	DLGAP1 MXRA8 CCDC80 PIEZO2 SPON1 COL14A1 CLMP	3.10e-06	192	144	7	dcd924d6eb67d33ee9f5d3e8ab6e1d4283d6b708
ToppCell	LPS_only-Stromal_mesenchymal\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	DLGAP1 MXRA8 CCDC80 PIEZO2 SPON1 COL14A1 PALLD	3.10e-06	192	144	7	162d8b5858d150ecbbd1c9bf2b19c6c9cd50a158
ToppCell	LPS-IL1RA+antiTNF-Stromal_mesenchymal\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	DLGAP1 MXRA8 CCDC80 PIEZO2 SPON1 COL14A1 PALLD	3.10e-06	192	144	7	3d0cb19f037f604253d7d728689aeaa94251e92b
ToppCell	LPS-IL1RA-Stromal_mesenchymal\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	MXRA8 CCDC80 PIEZO2 SPON1 COL14A1 CLMP PALLD	3.10e-06	192	144	7	4e47a02007f562f29ba5910df64d32a0167d0bd1
ToppCell	LPS_only-Stromal_mesenchymal-Matrix_Fibroblast\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	DLGAP1 MXRA8 CCDC80 PIEZO2 SPON1 COL14A1 CLMP	3.10e-06	192	144	7	ee085e04d5dcfb657522484ed20b8c1ddeccfe0c
ToppCell	renal_papilla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Fibroblast\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	TRPS1 MXRA8 ANO1 PIEZO2 SPON1 CLMP PALLD	3.10e-06	192	144	7	9333aba0d04203ccccad78d82bf6359922f810a7
ToppCell	PND07-Mesenchymal-Mesenchymal_structural-Fibroblastic-AF1-AF1_mature\|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	MXRA8 CCDC80 CAMK1G FAM171A1 SPON1 MACF1 PALLD	3.21e-06	193	144	7	8d05805295c5d3aa93aeb38be5fbefa81e1be1f0
ToppCell	Children_(3_yrs)-Mesenchymal-matrix_fibroblast_1_cell\|Children_(3_yrs) / Lineage, Cell type, age group and donor	DLGAP1 ANO1 PIEZO2 SPON1 MACF1 CLMP PALLD	3.21e-06	193	144	7	99525545552b371c86b18b6ea6f4897dc6e9a9ec
ToppCell	droplet-Liver-LIVER_HEP-30m-Endothelial-endothelial_cell_of_hepatic_sinusoid\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MXRA8 APBB2 ADGRG1 CCDC80 ADGRA2 FAM171A1 TJP1	3.21e-06	193	144	7	d485634c564b268e344b6a2863c26f6adaec9e38
ToppCell	LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	DLGAP1 MXRA8 CCDC80 PIEZO2 SPON1 COL14A1 CLMP	3.21e-06	193	144	7	fb28717fadd06c3840636d25409ce80c9254bd34
ToppCell	LPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	DLGAP1 SYNE1 CCDC80 PIEZO2 SPON1 COL14A1 CLMP	3.32e-06	194	144	7	60622bd2f75bfe4c37f721cb12f03dab33f2f58d
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Fibroblast\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	ADAMTSL1 CCDC80 GRIN2A SPON1 COL14A1 CLMP PALLD	3.32e-06	194	144	7	e03ba6caed59fa64d4d9b042593469d4a6a3dc10
ToppCell	PND07-Mesenchymal-Mesenchymal_structural-Fibroblastic\|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	MXRA8 CCDC80 FAM171A1 SPON1 MACF1 CLMP PALLD	3.43e-06	195	144	7	b616ee6f1d878935d293c8e0a8bbc5b4385301f0
ToppCell	PND10-Mesenchymal-Mesenchymal_structural-Fibroblastic-AF1-AF1_mature\|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	MXRA8 CCDC80 FAM171A1 SPON1 MACF1 CLMP PALLD	3.43e-06	195	144	7	1c1135be421af98cd0077bec1ff2c4158d42aa21
ToppCell	3'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_1-Adventitial_fibroblasts-Adventitial_fibroblasts_L.2.1.2.1\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	ADAMTSL1 MXRA8 CCDC80 PIEZO2 SPON1 COL14A1 CLMP	3.43e-06	195	144	7	f54bc4454270ff06e85596f98199372b50d0179f
ToppCell	PND10-Mesenchymal-Mesenchymal_structural\|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	MXRA8 CCDC80 FAM171A1 SPON1 MACF1 CLMP PALLD	3.43e-06	195	144	7	11d421bbbb71425d59cbdd673e052e00d5f0a768
ToppCell	PND10-Mesenchymal-Mesenchymal_structural-Fibroblastic-AF1\|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	MXRA8 CCDC80 FAM171A1 SPON1 MACF1 CLMP PALLD	3.43e-06	195	144	7	1f005ee1da66b539bd200aaa98f46edbbc7f12e4
ToppCell	PND10-Mesenchymal-Mesenchymal_structural-Fibroblastic\|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	MXRA8 CCDC80 FAM171A1 SPON1 MACF1 CLMP PALLD	3.43e-06	195	144	7	10f307aef8f4d9e71c501d5bcedb84d3be7a4d1b
ToppCell	PND07-Mesenchymal-Mesenchymal_structural\|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	MXRA8 CCDC80 FAM171A1 SPON1 MACF1 CLMP PALLD	3.43e-06	195	144	7	2f9a274b26fc528a85f50933ec2f4db1dc9da0ca
ToppCell	PCW_05-06-Mesenchymal\|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung	TRPS1 CCDC80 PIEZO2 COL14A1 CLMP MAML2 PALLD	3.55e-06	196	144	7	dca52c57ba35d9395cdbca8b881f12ece721b10f
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Mesenchymal-Fibroblast-Collagen-low_Matrisome-low_fibroblast\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	DLGAP1 ADAMTSL1 CAMK4 SPON1 COL14A1 CLMP PALLD	3.55e-06	196	144	7	ba869f7a86f37fd6d84d6ad69baca0e0faaf5887
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Mesenchymal-Fibroblast-Collagen-low_Matrisome-low_fibroblast-\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	DLGAP1 ADAMTSL1 CAMK4 SPON1 COL14A1 CLMP PALLD	3.55e-06	196	144	7	30ad56d49000e4ddce73b4443b3994564bd1e2d6
ToppCell	LPS_anti-TNF-Mesenchymal_fibroblastic-Fibroblasts-Activated_MatrixFB\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	SYNE1 CCDC80 LHX2 CBFA2T2 MACF1 COL14A1 CLMP	3.67e-06	197	144	7	fdb92985f7df0c280b87d3e43c2394e70786a2c7
ToppCell	COVID-19-Fibroblasts-Intermediate_pathological_FB\|COVID-19 / group, cell type (main and fine annotations)	APBB2 CCDC80 PIEZO2 SPON1 COL14A1 CLMP PALLD	3.67e-06	197	144	7	f1c8936986123a3151140c374fcd62d6705c530b
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-Fibroblast-Collagen+matrisome-high_fibroblast-\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	SYNE1 APBB2 CCDC80 SPON1 CLMP MAML2 PALLD	3.67e-06	197	144	7	85a8f1d18e0dd1d31341f5131eecd217553bf042
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-Fibroblast-Collagen+matrisome-high_fibroblast\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	SYNE1 APBB2 CCDC80 SPON1 CLMP MAML2 PALLD	3.67e-06	197	144	7	e8e3ba791dfaa0fab35e0329a5e34376f9ee6143
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	ADAMTSL1 SYNE1 CCDC80 SPON1 CLMP MAML2 PALLD	3.67e-06	197	144	7	9b480f9c799a244bfee64487abd8a1bf07c9a3a2
ToppCell	COVID-19-Fibroblasts\|COVID-19 / group, cell type (main and fine annotations)	APBB2 CCDC80 PIEZO2 SPON1 COL14A1 CLMP PALLD	3.67e-06	197	144	7	fb847f2277609c31fffcdf49517243ce0684facf
ToppCell	IPF-Stromal-Myofibroblast\|Stromal / Disease state, Lineage and Cell class	TRPS1 CDH23 PIEZO2 SPON1 MACF1 CLMP PALLD	3.67e-06	197	144	7	f304d42fc4936fe20996e07c8dccc698a6e5e5ef
ToppCell	COVID-19-lung-Fibroblast\|COVID-19 / Disease (COVID-19 only), tissue and cell type	MXRA8 CDH23 CCDC80 PIEZO2 SPON1 COL14A1 CLMP	3.80e-06	198	144	7	3ec01a55ade5e1627258cc3cfebb2c3207a4cb43
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-Fibroblast\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	ADAMTSL1 SYNE1 CCDC80 SPON1 CLMP MAML2 PALLD	3.80e-06	198	144	7	a860246bcea847249a78fd2e86ed8e04371060db
ToppCell	LPS_IL1RA-Mesenchymal_fibroblastic-Fibroblasts\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	POLD1 MXRA8 CCDC80 SPON1 COL14A1 CLMP PALLD	3.92e-06	199	144	7	ba586690f88fd051f449753bfe7603a2cb431782
ToppCell	distal-mesenchymal-Alveolar_Fibroblast-2\|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	MXRA8 ANO1 CCDC80 PIEZO2 SPON1 MACF1 PALLD	3.92e-06	199	144	7	28c1722deef3b8347371c7359be7c64b95780de3
ToppCell	LPS_IL1RA-Mesenchymal_fibroblastic-Fibroblasts-Diff_MatrixFB\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	POLD1 MXRA8 CCDC80 SPON1 COL14A1 CLMP PALLD	3.92e-06	199	144	7	38ed3bc7daa993d9edcf3e7834597ebb06dd24f8
ToppCell	LPS_IL1RA-Mesenchymal_fibroblastic\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	POLD1 MXRA8 CCDC80 SPON1 COL14A1 CLMP PALLD	3.92e-06	199	144	7	06a7d874ff7c4616577f6e59d3118717a8c47c00
ToppCell	Brain_organoid-organoid_Paulsen_bioRxiv-6_mon-Proliferating-Cycling_Progenitors\|6_mon / Sample Type, Dataset, Time_group, and Cell type.	MIS18BP1 E2F1 CENPK CEP55 DDIAS BRCA2 ZNF367	3.92e-06	199	144	7	a99516a5760f49a69b0fe45a9b2316e393252966
ToppCell	LPS_only-Mesenchymal_fibroblastic-Fibroblasts-Activated_MatrixFB\|LPS_only / Treatment groups by lineage, cell group, cell type	MYCBP2 POLD1 MXRA8 CCDC80 JAK2 COL14A1 CLMP	3.92e-06	199	144	7	fde2b65afde69f402f1b7b056eaa266e9fd5b227
Drug	Aceclofenac [89796-99-6]; Up 200; 11.2uM; PC3; HT_HG-U133A	SOX13 ZFPL1 PPP4R3A VPS13D CSNK1G2 COL14A1 SMAD5 ARMC8 BRWD1	4.52e-06	196	144	9	7269_UP
Drug	Nefopam hydrochloride [23327-57-3]; Up 200; 13.8uM; HL60; HT_HG-U133A	TBKBP1 E2F1 MLLT10 ADA VPS13D POLL PRKAG2 MAPK8 SMAD5	4.52e-06	196	144	9	2355_UP
Drug	pramipexole	DRD3 MAPK8 MAPK9	4.89e-06	6	144	3	ctd:C061333
Drug	Gramine [87-52-5]; Down 200; 23uM; MCF7; HT_HG-U133A	APBB2 E2F1 NEB JAK2 PHKA2 VPS13D NF2 NBEAL2 PLD2	4.91e-06	198	144	9	2799_DN
Drug	Glutethimide, para-amino [125-84-8]; Down 200; 17.2uM; MCF7; HT_HG-U133A	E2F1 ARHGAP35 ZFPL1 PPP4R3A JAK2 NF2 CBFA2T2 MACF1 CCDC9	5.11e-06	199	144	9	7421_DN
Drug	Ribavirin [36791-04-5]; Down 200; 16.4uM; PC3; HT_HG-U133A	MTF2 SOX13 ZFPL1 JAK2 PPP4R3B PHKA2 PLD2 ARMC8 BRWD1	5.11e-06	199	144	9	7316_DN
Drug	methyl methanesulfonate	MRE11 TBPL1 POLD1 ICE2 ADA PPP4R3B NF2 BRCA2 DROSHA MAPK8 MAPK9	2.11e-05	364	144	11	CID000004156
Drug	Aspidium	PRSS3 ACLY LILRA6 PRR12 LHX2 SUOX POLL LRBA	2.31e-05	184	144	8	CID000000815
Drug	Luteolin [491-70-3]; Down 200; 14uM; MCF7; HT_HG-U133A	ADGRG1 E2F1 JAK2 PPP4R3B LHX2 CCDC9 ARMC8 BRWD1	2.90e-05	190	144	8	3379_DN
Drug	Fenbufen [36330-85-5]; Down 200; 15.8uM; PC3; HT_HG-U133A	MIS18BP1 APBB2 MLLT10 NEB JAK2 BRCA2 POLL SMAD5	3.01e-05	191	144	8	4279_DN
Drug	Sanguinarine [2447-54-3]; Down 200; 12uM; MCF7; HT_HG-U133A	TRPS1 VPS13D SF3B3 MACF1 ZFYVE26 PRKAG2 SMAD5 BRWD1	3.01e-05	191	144	8	4168_DN
Drug	Trichostatin A, from Streptomyces sp.; Up 200; 0.1uM; HL60; HT_HG-U133A	TBKBP1 TRPS1 GATM ARHGAP35 LHX2 NF2 GPR153 PALLD	3.13e-05	192	144	8	3114_UP
Drug	(+/-)-blebbistatin; Up 200; 17uM; MCF7; HT_HG-U133A_EA	IDE MLLT10 ARHGAP35 NEB SOX13 PPP4R3A PLD2 MAPK8	3.37e-05	194	144	8	954_UP
Drug	Crotamiton [483-63-6]; Down 200; 19.6uM; HL60; HT_HG-U133A	CDHR2 TRPS1 APBB2 NEB ADA VPS13D NF2 POLL	3.49e-05	195	144	8	3050_DN
Drug	Nadolol [42200-33-9]; Down 200; 13uM; MCF7; HT_HG-U133A	SYNE1 ARHGAP35 ADGRA2 PPP4R3A VPS13D NF2 GPR153 MAPK8	3.62e-05	196	144	8	3359_DN
Drug	Pentetic acid [67-43-6]; Down 200; 10.2uM; HL60; HT_HG-U133A	PILRA APBB2 ARHGAP35 NEB ADA ZFPL1 ZFYVE26 SMAD5	3.62e-05	196	144	8	3049_DN
Drug	Fenspiride hydrochloride [5053-08-7]; Down 200; 13.4uM; MCF7; HT_HG-U133A	CAMK4 APBB2 ARHGAP35 PPP4R3A JAK2 VPS13D GPR153 MAPK8	3.76e-05	197	144	8	2269_DN
Drug	fludrocortisone acetate; Up 200; 1uM; MCF7; HG-U133A	MYCBP2 ZNF217 PHKA2 VPS13D PIEZO2 NBEAL2 JOSD1 MAPK8	3.76e-05	197	144	8	281_UP
Drug	5155877; Down 200; 10uM; PC3; HT_HG-U133A	TBKBP1 SYNE1 SOX13 PPP4R3B VPS13D NF2 CCDC9 BRWD1	3.89e-05	198	144	8	6544_DN
Drug	Megestrol acetate [595-33-5]; Down 200; 10.4uM; HL60; HT_HG-U133A	CDHR2 CAMK4 GATM ARHGAP35 NF2 POLL SMAD5 CPNE7	3.89e-05	198	144	8	3091_DN
Drug	N(6),N(6)-dimethyladenine	TJP1 MAPK8 MAPK9	3.94e-05	11	144	3	ctd:C001020
Drug	NSC229609	LCT SUOX	3.97e-05	2	144	2	CID000069530
Drug	Palmatine chloride [3486-67-7]; Up 200; 10.4uM; MCF7; HT_HG-U133A	MRE11 CAMK4 NEB NF2 GPR153 SPON1 COL14A1 CPNE7	4.04e-05	199	144	8	4957_UP
Drug	Diloxanide furoate [3736-81-0]; Down 200; 12.2uM; HL60; HT_HG-U133A	SYNE1 TRPS1 ADA ZFPL1 PPP4R3B NF2 MAPK8 SMAD5	4.18e-05	200	144	8	3062_DN
Drug	dinitrophenyl-bovine serum albumin	PLD2 MAPK8 MAPK9	5.23e-05	12	144	3	ctd:C034638
Disease	Prostatic Cancer, Castration-Resistant	ZNF217 CENPK ZNF367	8.60e-06	9	140	3	C3658266
Disease	Prostatic Neoplasms, Castration-Resistant	ZNF217 CENPK ZNF367	8.60e-06	9	140	3	C3658267
Disease	glucose metabolism decline measurement, cingulate cortex measurement	CDH23 PPP4R3A TBC1D8	8.60e-06	9	140	3	EFO_0007738, EFO_0009392
Disease	esophagus squamous cell carcinoma (is_implicated_in)	TET2 FAT1 BRCA2 COL14A1	6.22e-05	45	140	4	DOID:3748 (is_implicated_in)
Disease	Myelofibrosis	TET2 JAK2	1.33e-04	4	140	2	C0026987
Disease	liver cancer (implicated_via_orthology)	MRE11 JAK2	1.33e-04	4	140	2	DOID:3571 (implicated_via_orthology)
Disease	suntan	MYH7B TRPS1 PIEZO2 CBFA2T2 CPNE7	1.35e-04	103	140	5	EFO_0004279
Disease	polybrominated biphenyl measurement, gestational serum measurement, polybrominated diphenyl ether measurement	DLGAP1 ADAMTSL1	2.21e-04	5	140	2	EFO_0007961, EFO_0007962, EFO_0007964
Disease	Alzheimer's disease (is_marker_for)	MRE11 DRD3 E2F1 GRIN2A IDE MAPK8 MAPK9	2.35e-04	257	140	7	DOID:10652 (is_marker_for)
Disease	colorectal cancer (is_implicated_in)	GRIN2A LRP1B FAT1 NF2 MAPK9	2.86e-04	121	140	5	DOID:9256 (is_implicated_in)
Disease	brain disease (implicated_via_orthology)	MYCBP2 DROSHA	3.31e-04	6	140	2	DOID:936 (implicated_via_orthology)
Disease	glucagon measurement, glucose tolerance test	SPON1 MACF1	3.31e-04	6	140	2	EFO_0004307, EFO_0008463
Disease	Primary Myelofibrosis	TET2 JAK2	3.31e-04	6	140	2	C0001815
Disease	lung non-small cell carcinoma (is_implicated_in)	TET2 E2F1 LRP1B JAK2 FAT1	5.41e-04	139	140	5	DOID:3908 (is_implicated_in)
Disease	Polycythemia Vera	TET2 JAK2	6.14e-04	8	140	2	C0032463
Disease	colon cancer (is_implicated_in)	MRE11 ADA LRP1B	6.66e-04	36	140	3	DOID:219 (is_implicated_in)
Disease	hormone measurement	EXOC6 TPTE2P1 DDIAS RESF1	6.98e-04	84	140	4	EFO_0004730
Disease	Conventional (Clear Cell) Renal Cell Carcinoma	TET2 MLLT10 LRP1B NF2 MAPK8	7.19e-04	148	140	5	C0279702
Disease	Pancreatic carcinoma, familial	BRCA2 PALLD	7.87e-04	9	140	2	C2931038
Disease	glycogen storage disease (is_implicated_in)	PHKA2 PRKAG2	7.87e-04	9	140	2	DOID:2747 (is_implicated_in)
Disease	corpus callosum anterior volume measurement	ADAMTSL1 TRPS1 PPP4R3A	8.43e-04	39	140	3	EFO_0010295
Disease	diverticular disease	DOCK3 TBKBP1 TRPS1 ANO1 CENPK KCNIP4	9.45e-04	236	140	6	EFO_0009959
Disease	triglyceride measurement, low density lipoprotein cholesterol measurement	TBKBP1 TRPS1 BRCA2 ABCB11 BRWD1	1.20e-03	166	140	5	EFO_0004530, EFO_0004611
Disease	melanoma	E2F1 GRIN2A MLLT10 LRP1B NF2 BRCA2	1.22e-03	248	140	6	C0025202
Disease	aspartate aminotransferase measurement	MYH7B NAP1L4 MLLT10 ARHGAP35 NDUFA8 LCT TBC1D8 WDR11 NUP37 ABCB11 KCNIP4 LRBA	1.29e-03	904	140	12	EFO_0004736
Disease	Clear Cell Meningioma	MLLT10 NF2	1.43e-03	12	140	2	C0431121
Disease	Intraventricular Meningioma	MLLT10 NF2	1.43e-03	12	140	2	C1334271
Disease	Benign Meningioma	MLLT10 NF2	1.43e-03	12	140	2	C0281784
Disease	Intraorbital Meningioma	MLLT10 NF2	1.43e-03	12	140	2	C1334261
Disease	Olfactory Groove Meningioma	MLLT10 NF2	1.43e-03	12	140	2	C1335107
Disease	Angioblastic Meningioma	MLLT10 NF2	1.43e-03	12	140	2	C1527197
Disease	Trigeminal Neuralgia	MAPK8 MAPK9	1.43e-03	12	140	2	C0040997
Disease	Meningiomas, Multiple	MLLT10 NF2	1.43e-03	12	140	2	C0205834
Disease	Xanthomatous Meningioma	MLLT10 NF2	1.43e-03	12	140	2	C0457190
Disease	Angiomatous Meningioma	MLLT10 NF2	1.43e-03	12	140	2	C0334608
Disease	Psammomatous Meningioma	MLLT10 NF2	1.43e-03	12	140	2	C0334607
Disease	Fibrous Meningioma	MLLT10 NF2	1.43e-03	12	140	2	C0334606
Disease	Meningothelial meningioma	MLLT10 NF2	1.43e-03	12	140	2	C0334605
Disease	Hemangioblastic Meningioma	MLLT10 NF2	1.43e-03	12	140	2	C0334609
Disease	Transitional Meningioma	MLLT10 NF2	1.43e-03	12	140	2	C0334611
Disease	Hemangiopericytic Meningioma	MLLT10 NF2	1.43e-03	12	140	2	C0334610
Disease	Spinal Meningioma	MLLT10 NF2	1.43e-03	12	140	2	C0347515
Disease	Secondary Trigeminal Neuralgia	MAPK8 MAPK9	1.43e-03	12	140	2	C0393787
Disease	Trigeminal Neuralgia, Idiopathic	MAPK8 MAPK9	1.43e-03	12	140	2	C0393786
Disease	Intracranial Meningioma	MLLT10 NF2	1.43e-03	12	140	2	C0349604
Disease	Papillary Meningioma	MLLT10 NF2	1.43e-03	12	140	2	C3163622
Disease	Malignant Meningioma	MLLT10 NF2	1.43e-03	12	140	2	C0259785
Disease	Thrombocythemia, Essential	TET2 JAK2	1.43e-03	12	140	2	C0040028
Disease	Sphenoid Wing Meningioma	MLLT10 NF2	1.43e-03	12	140	2	C1565951
Disease	Posterior Fossa Meningioma	MLLT10 NF2	1.43e-03	12	140	2	C1565950
Disease	Parasagittal Meningioma	MLLT10 NF2	1.43e-03	12	140	2	C0751304
Disease	Cerebral Convexity Meningioma	MLLT10 NF2	1.43e-03	12	140	2	C0751303
Disease	Microcystic meningioma	MLLT10 NF2	1.43e-03	12	140	2	C1384408
Disease	Secretory meningioma	MLLT10 NF2	1.43e-03	12	140	2	C1384406
Disease	sleep duration	MYCBP2 KCTD8 CDH23 MLLT10 PRR12 PLD2 SMAD5	1.76e-03	362	140	7	EFO_0005271
Disease	C-reactive protein measurement	DOCK3 MTF2 HYKK TBPL1 TRPS1 KCTD8 MLLT10 EIF3CL CSNK1G2 ABCB11 JOSD1 MACF1 KCNIP4 PLD2	1.83e-03	1206	140	14	EFO_0004458
Disease	lung carcinoma, estrogen-receptor negative breast cancer, ovarian endometrioid carcinoma, colorectal cancer, prostate carcinoma, ovarian serous carcinoma, breast carcinoma, ovarian carcinoma, lung adenocarcinoma, squamous cell lung carcinoma	TET2 MXRA8 BRCA2	1.95e-03	52	140	3	EFO_0000305, EFO_0000571, EFO_0000708, EFO_0001071, EFO_0001075, EFO_0001663, EFO_1000650, EFO_1001515, EFO_1001516, MONDO_0005575
Disease	severe combined immunodeficiency (is_implicated_in)	ADA DCLRE1C	1.96e-03	14	140	2	DOID:627 (is_implicated_in)
Disease	Hereditary Breast and Ovarian Cancer Syndrome	MRE11 BRCA2	1.96e-03	14	140	2	C0677776
Disease	pneumonia, COVID-19	ADAMTSL1 LRP1B TBC1D8 FAT1	2.10e-03	113	140	4	EFO_0003106, MONDO_0100096
Disease	Colorectal Neoplasms	TET2 POLD1 SYNE1 GRIN2A FAT1 ABCB11	2.13e-03	277	140	6	C0009404
Disease	R-6-hydroxywarfarin measurement	TRPS1 LRP1B LRBA PALLD	2.16e-03	114	140	4	EFO_0803327
Disease	myelodysplastic syndrome (implicated_via_orthology)	TET2 PRPF8	2.25e-03	15	140	2	DOID:0050908 (implicated_via_orthology)
Disease	pancreatic adenocarcinoma (is_implicated_in)	E2F1 MAPK9	2.25e-03	15	140	2	DOID:4074 (is_implicated_in)
Disease	Cocaine-Related Disorders	DRD3 CAMK4 ICE2 SMAD5	2.38e-03	117	140	4	C0236736
Disease	colorectal cancer	DOCK3 TET2 DLGAP1 TRPS1 ANO1 MACF1 KCNIP4 CLMP LRBA	2.43e-03	604	140	9	MONDO_0005575
Disease	cognitive behavioural therapy	NEB SOX13 DCLRE1C	2.67e-03	58	140	3	EFO_0007820
Disease	metabolic syndrome	EXOC6 TRPS1 MLLT10 PPP4R3B ABCB11	2.71e-03	200	140	5	EFO_0000195
Disease	adverse effect, response to xenobiotic stimulus	LRP1B SOX13 COL14A1	2.80e-03	59	140	3	EFO_0009658, GO_0009410
Disease	Acute myeloid leukemia	MLLT10 JAK2	2.90e-03	17	140	2	cv:C0023467
Disease	bacteriemia	DOCK3 PALLD	2.90e-03	17	140	2	EFO_0003033
Disease	LEUKEMIA, ACUTE MYELOID	MLLT10 JAK2	2.90e-03	17	140	2	601626
Disease	eosinophil percentage of leukocytes	DOCK3 EXOC6 MTF2 ICE2 ANO1 NAP1L4 NUP205 JAK2 RESF1 SUOX	3.03e-03	746	140	10	EFO_0007991
Disease	melanoma	DOCK3 TET2 MYH7B CBFA2T2	3.11e-03	126	140	4	EFO_0000756
Disease	Cocaine Abuse	DRD3 CAMK4 ICE2 SMAD5	3.20e-03	127	140	4	C0009171
Disease	Sarcomatoid Renal Cell Carcinoma	TET2 MLLT10 LRP1B NF2	3.29e-03	128	140	4	C1266043
Disease	Chromophobe Renal Cell Carcinoma	TET2 MLLT10 LRP1B NF2	3.29e-03	128	140	4	C1266042
Disease	Collecting Duct Carcinoma of the Kidney	TET2 MLLT10 LRP1B NF2	3.29e-03	128	140	4	C1266044
Disease	Papillary Renal Cell Carcinoma	TET2 MLLT10 LRP1B NF2	3.29e-03	128	140	4	C1306837
Disease	Renal Cell Carcinoma	TET2 MLLT10 LRP1B NF2	3.29e-03	128	140	4	C0007134
Disease	household income	TET2 CASC3 LRP1B SUOX FARP1 ZNF367	3.37e-03	304	140	6	EFO_0009695
Disease	Omenn Syndrome	ADA DCLRE1C	3.63e-03	19	140	2	C2700553
Disease	Meningioma	MLLT10 NF2	3.63e-03	19	140	2	C0025286
Disease	squamous cell carcinoma	TRPS1 BRCA2 SUOX	4.01e-03	67	140	3	EFO_0000707
Disease	Deaf Mutism	POLD1 SERAC1	4.02e-03	20	140	2	C4082305
Disease	Deafness, Acquired	POLD1 SERAC1	4.02e-03	20	140	2	C0751068
Disease	Hearing Loss, Extreme	POLD1 SERAC1	4.02e-03	20	140	2	C0086395
Disease	Complete Hearing Loss	POLD1 SERAC1	4.02e-03	20	140	2	C0581883
Disease	Bilateral Deafness	POLD1 SERAC1	4.02e-03	20	140	2	C3665473
Disease	Severe Combined Immunodeficiency	ADA DCLRE1C	4.02e-03	20	140	2	C0085110
Disease	Prelingual Deafness	POLD1 SERAC1	4.02e-03	20	140	2	C0011052
Disease	Cocaine Dependence	DRD3 CAMK4 ICE2 SMAD5	4.41e-03	139	140	4	C0600427
Disease	osteoarthritis, hip, osteoarthritis, knee, total joint arthroplasty	MAML2 BRWD1	4.42e-03	21	140	2	EFO_0004616, EFO_0010726, EFO_1000786
Disease	forced expiratory volume	TET2 ADAMTSL1 HYKK SYNE1 LHX3 GRIN2A SUOX WDR11 DROSHA MEIOSIN	4.49e-03	789	140	10	EFO_0004314

Protein segments in the cluster

Peptide	Gene	Start	Entry
PLESYKHEPERLENR	PRKAG2	176	Q9UGJ0
KHEPERLENRIYASS	PRKAG2	181	Q9UGJ0
RYSPHLLANSKVEPI	ADA	101	P00813
AETFRPKDDLYPLLH	CFAP43	241	Q8NDM7
YASLKLRNAPHPDDD	APBB2	391	Q92870
PYSSVEKDQHRIALD	PRMT9	606	Q6P2P2
LEKESHRRSYPLNAA	ADGRA2	1286	Q96PE1
PKCNIQYPATEHRDL	CEP55	441	Q53EZ4
TFHYPSRPEVKILND	ABCB11	426	O95342
LQYKRTAVEHRSDSP	DLGAP1	121	O14490
FIHQYDARKTPNEPL	C2orf73	151	Q8N5S3
PPDRERQSFYHLVAT	CDH23	1591	Q9H251
SENLYPPSRKDQHRE	CCDC80	411	Q76M96
SRYLDHPQPSKAEQD	POLL	136	Q9UGP5
TPKSERYEHVLEALN	MTF2	311	Q9Y483
ISAHVREKPDDPLNY	NDUFA11	76	Q86Y39
RKLQFYEDRHQLPAP	JAK2	761	O60674
YDPALSQPRKHREFL	PPP4R3A	226	Q6IN85
KDLPSADSVQYRHLP	NUP205	571	Q92621
PPSNRYETLLKQRHV	CYFIP1	741	Q7L576
ELPLNSKPRSYAHIE	FAT1	3986	Q14517
PDKRISVDEALRHPY	MAPK9	306	P45984
LQERLDNVPHTPSSY	NAP1L4	41	Q99733
EHQQKEPRAPDSTAY	FAM171A1	771	Q5VUB5
DYLRDKQLALPEHFP	KCTD8	111	Q6ZWB6
HLSDETNLNSPIRPY	LRP1B	2201	Q9NZR2
LKHSRIYLPPEASSQ	MIS18BP1	6	Q6P0N0
APDYRVHIISFKDPN	GATM	286	P50440
QQERYKEIEHSSPPS	GPR155	851	Q7Z3F1
DSPYIIPQHRSLEDR	DIO3	211	P55073
INIYHSETKDIDNPP	IMPG1	26	Q17R60
PCRLPDHSENQAYKT	IMPG1	746	Q17R60
VHRDLKPENLLYATP	CAMK4	161	Q16566
PYHEKALVNRDRTLP	FICD	171	Q9BVA6
LEPIKSRAPQLHLEY	CSNK1G2	76	P78368
SQQPEELRDLYSKHL	ADAMTSL1	1086	Q8N6G6
NYIKEHSPRQRPARE	FAM199X	246	Q6PEV8
LEDIATSHLYREPNK	CBFA2T2	296	O43439
KRRSDSPPHIYAVAD	MYH7B	186	A7E2Y1
ASKRISVDEALQHPY	MAPK8	306	P45983
HRYIQDPNKIPETLD	DDIAS	91	Q8IXT1
YLQVPPTRRFSHDDA	GPR153	386	Q6NV75
TYPVLKEDAPRQHVE	KCNIP4	196	Q6PIL6
RRVPYHDPQISKSLE	MDM1	56	Q8TC05
TALPQDERLPHYLRD	OPN5	6	Q6U736
SKYRDILEPQNERHS	LRBA	1546	P50851
HKTPRLNPPSYEDDQ	LCT	1216	P09848
AEHLDRDQPYPSSQK	LHX2	251	P50458
YNTSPKPARHVREQL	LHX3	176	Q9UBR4
AAPPQIYHEKQRREL	JOSD1	21	Q15040
PASHAKDYTVENLIR	LILRA6	436	Q6PI73
RYLKLKQQSPPDHEE	ANO1	691	Q5XXA6
PDHDIYLAAQPRKDL	KBTBD7	391	Q8WVZ9
DITRSSYPQNKRPVH	NUP37	236	Q8NFH4
LEYDPALAQPKRHRE	PPP4R3B	226	Q5MIZ7
PHPRQKLVFYDSSED	MEIOSIN	301	C9JSJ3
PTLRSVYDDQPNAHK	EXOC6	31	Q8TAG9
RVIKYSAPVNPHLRE	MDGA2	731	Q7Z553
LHPNKDAYRPTTDAD	MACF1	7106	Q9UPN3
HRDLKPENLLYLTPE	CAMK1G	141	Q96NX5
DPNERYTCEKALSHP	CAMK1G	261	Q96NX5
LHIYDPENRLTPKIS	NF2	241	P35240
LEYDPALDQPKRHRD	PPP4R3C	226	Q6ZMV5
ISPKSDHYTIQRDLD	PALLD	1041	Q8WX93
NRHLSRPPPDYKDQR	MAML2	791	Q8IZL2
AEPEVTYHRLRPQDK	PDP2	391	Q9P2J9
HRPLKSPQNETLYSV	PILRA	286	Q9UKJ1
DYKAHQRQLTPPEGS	EIF3CL	516	B5ME19
SRHYVDRLFDPDPQK	ARMC8	21	Q8IUR7
RDINDHRPTFPQSLY	CDHR2	471	Q9BYE9
DPNAEKLVSRYHPQI	ICE2	266	Q659A1
KVRPLPSYDDQNFHV	HYKK	36	A2RU49
LSPVPRNAEHYKQRH	BCLAF3	16	A2AJT9
GYDIRSAHNPDDIKP	CASC3	241	O15234
TPEAELPKREHLQYL	DCLRE1C	656	Q96SD1
PPVKRRLDLETDHQY	E2F1	86	Q01094
EDRPLREFLHYPSQT	DOCK3	1271	Q8IZD9
HEENTTKPYLPSRAL	BRCA2	2876	P51587
PPDHTQLQEELTRYL	FARP1	121	Q9Y4F1
RPQAKAAPRAYSDHD	CCDC9	351	Q9Y3X0
KDALVSQPTRYLHPE	COL14A1	1266	Q05707
HFTVNPKPRVEYIDR	BTBD1	306	Q9H0C5
RIPPKYEVSHDFAIN	CPNE7	441	Q9UBL6
VKRNDPDGPHSDRIY	DPP8	86	Q6V1X1
NRLFDVPHDPYVKIS	CENPK	221	Q9BS16
LHYKPTPDLRISIEN	ADGRG1	46	Q9Y653
RSYEELVLSNKHVAP	BRWD1	61	Q9NSI6
LHYKRRPSQGPDQER	GDF9	281	O60383
QSEKPPHYLESRVEA	IDE	851	P14735
RSYGEPHKRPEVQNS	SEC24B	646	O95487
TRPKSPEEYLHNCLI	CFAP47	1816	Q6ZTR5
PRESELYQKEVSHLN	POLD1	1031	P28340
VKTDRPLPENPYHSR	NDUFA8	131	P51970
PHSVHRLAQSYLKEP	DDX43	431	Q9NXZ2
QTLSPDPAHLELKRY	DRD3	241	P35462
EDPNRLHYDPAELKL	PHKA2	306	P46019
ASRPHINSALYVEDK	nan	466	A6NNC1
HRKSKEADRQYDIPP	MINAR1	761	Q9UPX6
KEIPERDSRYSQPLH	MAP3K15	681	Q6ZN16
LYERLFQHKNPEDPT	QARS1	691	P47897
PSERRSPERLKHYDD	DROSHA	216	Q9NRR4
SEKTHPKDYPRRANH	SPON1	216	Q9HCB6
VLHPQYRTSQPIKAD	SERAC1	381	Q96JX3
REPLRLEHKYQPASV	SAXO1	151	Q8IYX7
VHESSNRLYDLPAKR	SYNE1	3196	Q8NF91
DLAPHLDPLAYEKAR	SYNE1	4841	Q8NF91
KILHAYNPSRDSEVV	TMEM131L	111	A2VDJ0
ASVYPRKPQAVERHV	TOGARAM2	911	Q6ZUX3
HLLLYENPQDTKESP	FER1L5	1131	A0AVI2
EHLQALLTPYEPDKS	NBPF10	396	Q6P3W6
YTPQDPARNEIHSDK	RESF1	1031	Q9HCM1
PARNEIHSDKAPVLY	RESF1	1036	Q9HCM1
THYSPQRERPLAADD	NBEAL2	1071	Q6ZNJ1
LYPHPQQLSREEKRR	NHLH2	56	Q02577
APQAEDHSSRILYPR	SCOC	56	Q9UIL1
ASEYDKQHSILPARV	MYCBP2	3481	O75592
TPYELAKEDPQRYHL	PRR12	686	Q9ULL5
RTTKAEHFYAREPEP	TEX45	286	Q8NA69
HQPEKPLVRLRVDYS	MRE11	356	P49959
KPRNEEENIYSVPHD	ARHGAP35	1096	Q9NRY4
SSRDVQPVAYEEPKH	SMAD5	256	Q99717
KDYVRQHFPATPLLD	ACLY	991	P53396
EPIVLQSVPHDRYNK	MLLT10	121	P55197
DERLPPKSRIDYNHP	CLMP	176	Q9H6B4
PAEFLYRIDQPKETH	C11orf54	296	Q9H0W9
LEYDKLEERPHLPST	CNOT2	516	Q9NZN8
PLRFSRENSEKIHPY	CYP4Z1	426	Q86W10
ARDLIQRYLTEHPDP	PRPF8	1106	Q6P2Q9
NSKNLPPEYDTHGRI	ZNF567	126	Q8N184
SHQREIPLPSLSKYE	TRPS1	991	Q9UHF7
RLPEFTKNNRPHASY	TBPL1	116	P62380
EQARLSRQHLEKYPD	SOX13	476	Q9UN79
YRLHIPPALTENDRD	TBC1D8	921	O95759
IPSKEDNTIYRLAHP	PIEZO2	821	Q9H5I5
LQYTPRKFVIHPESN	SF3B3	781	Q15393
IRHPKYNRDTLDNDI	PRSS3	151	P35030
FSEHDKTLYRIPEPQ	TJP1	1316	Q07157
YRPSVDCHEKPLNLS	ZNF217	676	O75362
DQKEPPSHQYLSLTL	USP30	106	Q70CQ3
YADDPVRHPALKVNS	SUOX	176	P51687
ERLYLPRNELDNPHK	TPTE2P1	41	Q5T6R2
HPYARLKREEPTDTL	ZNF367	246	Q7RTV3
DASRDLLLAIHPPNY	WDR11	126	Q9BZH6
KEQTRDLVPPTQHYL	TET2	546	Q6N021
ERTLAERAYAKPPSH	TBKBP1	436	A7MCY6
LSPEVYLKRPAHSDD	PLD2	366	O14939
FPYPQREKRSDSVIH	ZFYVE26	1731	Q68DK2
PLTHAPRKVYDTRDD	ZFPL1	206	O95159
FAAERHPREYSKAPE	VPS13D	2166	Q5THJ4
ERAELAHSPLPAKYI	MXRA8	416	Q9BRK3
NRTHSLKSPRYLPEE	GRIN2A	1041	Q12879
KENLHYTTVADRPDI	NEB	5731	P20929